Nature Biotechnology

Bluesky @natbiotech.nature.com

⚔ Compare ☆ Watch Own this channel?

🔄 Data last refreshed 11 days ago

🤝

Make a deal with Nature Biotechnology

🔒 Paid proposals held safely in escrow — released only when the work's approved.

Followers

13.7K

Account age

1 yrs

🧰 Free analysis for Nature Biotechnology

🕵️ Fake follower check 📊 Engagement rate 💰 What they charge

Known for

The July issue is live nature.com/nbt/volumes/...

On the cover, @ycongzhang.bsky.social @efranzosa.bsky.social @hutlab.bsky.social introduce FUGAsseM, a method that uses microbial community data to infer the functions of previously uncharacterized gene products go.nature.com/435C4lp
rdcu.be/ftNUV

13 views The July issue is live nature.com/nbt/volumes/... On the cover, @ycongzhang.bsky.social @efranzosa.bsky.social @hutlab.bsky.social introduce FUGAsseM, a method that uses microbial community data to infer the functions of previously uncharacterized gene products go.nature.com/435C4lp rdcu.be/ftNUV

Quantum computing in transition
Hybrid quantum–classical computers will achieve quantum advantage in biotechnology, bridging the time until a full quantum computer becomes available www.nature.com/articles/s41...

12 views Quantum computing in transition Hybrid quantum–classical computers will achieve quantum advantage in biotechnology, bridging the time until a full quantum computer becomes available www.nature.com/articles/s41...

For years, the idea of targeted protein degradation stalled because PROTACs were too large and unstable for clinical use. However, in the beginning of May, @fda.gov approved the use of the first PROTAC for adults with a certain form of metastatic breast cancer go.nature.com/4x3NYt7

10 views For years, the idea of targeted protein degradation stalled because PROTACs were too large and unstable for clinical use. However, in the beginning of May, @fda.gov approved the use of the first PROTAC for adults with a certain form of metastatic breast cancer go.nature.com/4x3NYt7

8 views Frontier AI companies as biotech acquirers www.nature.com/articles/s41...

📊 Post engagement

Avg engagement / post

0.1%

Engagement vs followers

Nov 2024

On Bluesky since

🔥 Top post: The July issue is live nature.com/nbt/volumes/... On the cover, · 13 likes + reposts

📊 Activity & format

Posting cadence

1.9 / week

A lower-frequency account — each post lands with more weight.

Content mix

Mostly images

Recent: 0 text · 12 image · 0 video.

Recent posts

View on Bluesky ↗

🔥 Top post The July issue is live nature.com/nbt/volumes/... On the cover, @ycongzhang.bsky.social @efranzosa.bsky.social @hutlab.bsky.social introduce FUGAsseM, a method that uses microbial community data to infer the functions of previously uncharacterized gene products go.nature.com/43… ★ 13

The SynCell Asia Initiative outlines a strategy for developing core functional modules followed by their systems-level integration through the establishment of a centralized, AI-driven biofoundry go.nature.com/4tW9FZg rdcu.be/fugoc

Quantum computing in transition Hybrid quantum–classical computers will achieve quantum advantage in biotechnology, bridging the time until a full quantum computer becomes available www.nature.com/articles/s41... ★ 12

Frontier AI companies as biotech acquirers www.nature.com/articles/s41... ★ 8

Quantum computing in transition www.nature.com/articles/s41... ★ 8

For years, the idea of targeted protein degradation stalled because PROTACs were too large and unstable for clinical use. However, in the beginning of May, @fda.gov approved the use of the first PROTAC for adults with a certain form of met… ★ 10

Educating for translation www.nature.com/articles/s41... ★ 2

Marked for destruction The significance of the first FDA-approved PROTAC lies not in proving that targeted protein degradation is superior to conventional therapies, but in proving that degrading proteins is possible as a therapeutic go.na… ★ 5

The June issue is live www.nature.com/nbt/volumes/... On the cover, Liu et al. present a solid tumor system that supports CAR‑T delivery and real‑time analysis of tumor–CAR‑T dynamics, evaluation of engineering strategies, and identificat… ★ 3

RNA at the Bench and Bedside is back for a 5th time, covering all the latest advances in nucleic acid medicines, from clinical trials to AI methods. Organized in partnership with Ionis Pharma, Alnylam & UCSD School of Medicine. Register no… ★ 6

Marked for destruction go.nature.com/4x3NYt7 ★ 3

Circling back to RNA vaccines While circRNA is often framed as a more stable, longer-lasting alternative to linear mRNA, its real-world advantages remain largely theoretical, and it is unclear whether greater molecular stability will trans… ★ 6

🦋 Handle & authenticity

✅ Domain-verified

@natbiotech.nature.com

The handle is the domain natbiotech.nature.com. On Bluesky a domain handle proves the owner controls that website — so this is verifiably the real natbiotech.nature.com account, not an impersonator.

On Bluesky since

Nov 2024

Joined after Bluesky opened to the public — a settled account with a real history.

💡 Facts

🗓️Joined Bluesky in 2024 — 1 year ago.

👁️Averages 7 views per post.

📤Posts about 1.9× per week.

🏅Earned the 10K Followers for passing 10K followers.

🛡️ Audience credibility

40/100

Low Credibility score

68%

Mixed Real audience

Medium Fake-follower risk

Medium Data confidence

Est. 68% real, active audience · Medium fake-follower risk.
Low engagement (~0.1% of followers engage each post) — a sign of an inflated or inactive audience.

Heuristic estimate from engagement, follower ratios, account age & growth — a screening signal, not a guarantee.